(Z)-3-(2-pyridylmethylene)-1-azabicyclo[2.2.2]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: (Z)-3-(2-pyridylmethylene)-1-azabicyclo[2.2.2]octane
• 英文别名: (3Z)-3-(pyridin-2-ylmethylidene)-1-azabicyclo[2.2.2]octane
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: MVQHXSQFWKKAOZ-FMIVXFBMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (2-picolyl)trimethylsilane 、 3-奎宁环酮 在 2,2,6,6-四甲基哌啶 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 1.33h， 生成 (E)-3-(2-pyridylmethylene)-1-azabicyclo[2.2.2]octane 、 (Z)-3-(2-pyridylmethylene)-1-azabicyclo[2.2.2]octane
  参考文献：
  名称：

  Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptors

  摘要：

  Bioisosteric replacement of the isoxazole heterocycle in (3-methyl-5-isoxazolyl)methylene-azacyclic compounds with pyridine, oxadiazole, or an acyl group resulted in ligands with high to moderate affinity for the central nicotinic cholinergic receptors (IC50 = 2.0 to IC50 > 1000 nM) labeled by [H-3]methylcarbamylcholine. Additionally, further support of an important distance parameter for high-affinity nicotinic compounds has been provided. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00063-8

文献信息

• NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS
  申请人：NOVO NORDISK A/S

  公开号：EP0853621A1

  公开（公告）日：1998-07-22
• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.
• [EN] NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES AZACYCLIQUES OU AZABICYCLIQUES A SUBSTITUTION
  申请人：NOVO NORDISK A/S

  公开号：WO1997011072A1

  公开（公告）日：1997-03-27

  (EN) The present invention relates to therapeutically active heterocyclic compounds, to methods for their preparation and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.(FR) Cette invention a trait à des composés hétérocycliques à activité thérapeutique, à des procédés permettant leur préparation ainsi qu'à des compositions pharmaceutiques les contenant. Ces nouveaux composés se révèlent utiles dans le traitement de maladies du système nerveux central liées à un dysfonctionnement du système cholinergique nicotinique.
• Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptors
  作者：Preben H. Olesen、Janne E. Tønder、John Bondo Hansen、Holger C. Hansen、Karin Rimvall

  DOI：10.1016/s0968-0896(00)00063-8

  日期：2000.6

  Bioisosteric replacement of the isoxazole heterocycle in (3-methyl-5-isoxazolyl)methylene-azacyclic compounds with pyridine, oxadiazole, or an acyl group resulted in ligands with high to moderate affinity for the central nicotinic cholinergic receptors (IC50 = 2.0 to IC50 > 1000 nM) labeled by [H-3]methylcarbamylcholine. Additionally, further support of an important distance parameter for high-affinity nicotinic compounds has been provided. (C) 2000 Elsevier Science Ltd. All rights reserved.